Board of Directors

Ari Bousbib is chairman and chief executive officer of IQVIA. Mr. Bousbib assumed this position in October 2016 following the merger of Quintiles and IMS Health. From 2010 until the merger, he served as chairman and CEO of IMS Health, leading the company’s IPO in 2014. Prior to his appointment at IMS Health, Mr. Bousbib spent 14 years at United Technologies Corporation (UTC), where he held several senior leadership positions. He joined UTC in 1997 as chief strategy and development officer, became chief operating officer of Otis Elevator Company in 2000, and president and chief executive of Otis in 2002. In 2008, Ari was appointed president of UTC Commercial Companies with executive leadership responsibility for the worldwide operations of Otis, Carrier, UTC Fire and Security and UTC Power. He was also a former partner at global management and technology consulting firm Booz Allen Hamilton. Mr. Bousbib currently serves on the board of directors of The Home Depot, Inc. He previously served on the board of directors of Best Buy, Inc. Mr. Bousbib is also a member of the Harvard Medical School Health Care Policy Advisory Council. Mr. Bousbib has an MBA from Columbia University and a Master of Science degree in Mathematics and Mechanical Engineering from Ecole Superieure des Travaux Publics, Paris.

Carol J. Burt has been serving as a director of IQVIA since February 2019 and currently chairs the Leadership Development and Compensation Committee and is a member of the Audit Committee. Ms. Burt has been a principal of Burt-Hilliard Investments since 2008. She also serves on the operating council and as a senior advisor to Consonance Capital Partners, which she joined in 2013. From 1997 to 2007, Ms. Burt was an executive officer of WellPoint, Inc. (f/k/a Anthem, Inc. and now Elevance Health, Inc.), lastly as Senior Vice President, Corporate Finance and Development. Prior to that, Ms. Burt held various positions at Chase Securities (now JPMorgan Chase), lastly as founder, managing director and head of its Health Care Banking Group. Ms. Burt currently serves on the board of directors of ResMed Inc., a New York Stock Exchange listed company. Ms. Burt is a member of the board of directors of WellDyneRx, LLC. She previously served on the boards of directors of Envision Healthcare Corporation, WellCare Health Plans, Inc., Vanguard Health Systems and Transitional Hospitals Corporation. She is also a member of Women Corporate Directors and International Women’s Forum. Ms. Burt has a Bachelor of Business Administration degree from the University of Houston, where she graduated magna cum laude.

John G. Danhakl has been serving as a director of IQVIA since October 2016 and is a member of the Leadership Development and Compensation Committee and the Nominating and Governance Committee. Prior to this, Mr. Danhakl served as a director of IMS Health from February 2010 until October 2016. He is a Managing Partner at Leonard Green & Partners, which he joined in 1995. Previously, Mr. Danhakl was a Managing Director of Donaldson, Lufkin & Jenrette Securities Corporation, which he joined in 1990. From 1985 until 1990, he was a Vice President in corporate finance at Drexel Burnham Lambert, Inc. Mr. Danhakl currently serves as a member of the boards of directors of Life Time Group Holdings, Inc., Mister Car Wash, Inc., CNG (Charter Next Generation), Crunch, Lakeshore Learning, Ownership Works, Parts Town, Pye-Barker Fire Safety, LLC and WellSky Corporation. Mr. Danhakl holds an MBA from Harvard Business School and a Bachelor of Arts degree in Economics from the University of California at Berkeley.

James A. Fasano has been serving as a director of IQVIA since October 2016 and currently chairs the Audit Committee and is a member of the Leadership Development and Compensation Committee. Prior to this, Mr. Fasano served as a director of IMS Health from January 2015 until October 2016. He is an Adjunct Professor at the University of Chicago Booth School of Business. Previously, Mr. Fasano was a Managing Director responsible for leading Canada Pension Plan Investment Board’s Funds, Secondaries & Co-investments group and led CPPIB’s Principal Investing group. Prior to joining CPPIB in 2004, Mr. Fasano worked in the Investment Banking group at Merrill Lynch & Co., was a member of the Mergers & Acquisitions group at RBC Capital Markets and was a Commissioned Officer in the Canadian Armed Forces. He has an MBA from the University of Chicago Graduate School of Business and a Bachelor of Engineering degree from the Royal Military College of Canada.

Colleen A. Goggins has been serving as a director of IQVIA since July 2017 and is currently the chair of the Nominating and Governance Committee and is a member of the Audit Committee. She also leads sustainability oversight for the IQVIA Board. Ms. Goggins is a member of the supervisory board for Bayer AG. She previously served on the boards of directors for the Bausch Health Companies Inc. (f/k/a Valeant Pharmaceuticals International), The Toronto-Dominion Bank and SIG Combibloc Group. Previously, she was a member of Johnson & Johnson's Executive Committee and Worldwide Chairman of the Consumer Group, among other roles at Johnson & Johnson. Ms. Goggins is a member of Citymeals-on-Wheels New York City and University of Wisconsin Foundation. She is also a member of the board of trustees of Institute of International Education. Ms. Goggins has a Master of Arts degree in Management, from the Kellogg School of Management, Northwestern University and a Bachelor of Science degree in Food Chemistry from the University of Wisconsin-Madison.

William G. Kaelin Jr., M.D. has been serving as a director of IQVIA since November 2025 and is a member of the Nominating and Governance Committee. Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School.  Dr. Kaelin became an independent investigator at Dana-Farber in 1992 and professor of medicine at Harvard Medical School in 2002. He joined the Howard Hughes Medical Institute in 1998. In 2019, Dr. Kaelin won the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein.  Dr. Kaelin currently serves on the board of directors of Eli Lilly and Company, LifeMine Therapeutics, and the Damon-Runyon Cancer Research Foundation. He previously served on the National Cancer Institute board of scientific advisers, the American Association for Cancer Research board of trustees and the Institute of Medicine National Cancer Policy board. He is a member of the American Society of Clinical Investigation and the American College of Physicians and was recently a Duke University trustee. Dr. Kaelin holds a Doctor of Medicine from Duke University School of Medicine and a Bachelor of Arts in Mathematics and Associate Bachelor in Chemistry from Duke University.

John M. Leonard, M.D. has been serving as a director of IQVIA since October 2016 and is our Lead Director. He is a member of the Audit Committee, the Leadership Development and Compensation Committee, and the Nominating and Governance Committee. Prior to this, Dr. Leonard served as a director of Quintiles from February 2015 until October 2016. Dr. Leonard is the President and Chief Executive Officer as well as a director at Intellia Therapeutics, Inc. He joined Intellia in 2014, where he has also held the roles of Executive Vice President, Research and Development and Chief Medical Officer. Previously, Dr. Leonard was the Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie Inc. and was Senior Vice President of Global Pharmaceutical Research and Development, among other roles, at Abbott Laboratories. Dr. Leonard has a bachelor’s degree in Biochemistry from the University of Wisconsin at Madison and a Doctorate in Medicine from Johns Hopkins University in Baltimore, MD. He completed an Internship and Residency in Internal Medicine at Stanford University Hospital followed by a Postdoctoral Fellowship in Molecular Virology at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Leslie Wims Morris has been serving as a director of IQVIA since January 2022 and is a member of the Nominating and Governance Committee. Ms. Wims Morris is the Chief Executive Officer of JPMorgan Chase’s automotive business, Chase Auto. Prior to this role, Ms. Wims Morris served in a variety of roles at JPMorgan Chase, including as President of Private Label Captive Finance for Chase Auto overseeing automotive partnerships with a number of key global manufacturers and as Managing Director and Head of Corporate Development for JPMorgan Chase’s Consumer & Community Banking business. Prior to JPMorgan Chase, Ms. Wims Morris was Vice President of Executive Partnerships at American Express, Senior Vice President of Strategy and Business Development at Broadridge Financial Solutions and Senior Vice President at Jefferies & Company. She presently serves as Vice Chair on the board of trustees for the Dance Theatre of Harlem. Ms. Wims Morris holds an MBA from the Harvard Business School and a Bachelor of Arts degree in English from Yale University.

Sheila A. Stamps has been serving as a director of IQVIA since January 2022 and is a member of the Audit Committee. Most recently, Ms. Stamps served as Executive Vice President, Corporate Strategy and Investor Relations at DBI, LLC. Prior to this she was a Commissioner on the board of the New York State Insurance Fund, a Director of Pensions and Cash Management at New York State Common Retirement Fund and as, Managing Director at Bank of America and Managing Director at Bank One Corporation (now JPMorgan Chase). Ms. Stamps currently serves on the board of directors of MFA Financial, Inc., a publicly traded company. She previously served on the boards of directors of Atlas Air Worldwide Holdings, Inc., Pitney Bowes Inc., CIT Group, Inc. and Forest Road Acquisition Corp. Ms. Stamps is also a member of the board of trustees at Bankinter Innovation Foundation. Ms. Stamps has an MBA, Finance, from the University of Chicago and a Bachelor of Science degree in Management from Duke University.